Re: Broker Meeting 23 Feb

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Broker Meeting 23 Feb

in response to

Re: Broker Meeting 23 Feb

SanFrancisco99

posted on Mar 01, 2017 12:37PM

Thank you for sharing Tada! Did they mention anything about the current status of the ZEN-3694 stand alone trial? Last we heard, they had found the maximally tolerated dose for the once per day/everyday dosing, and were proceeding to a new cohort with an intermittent dosing as opposed to every day dosing.